Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Shah

Interventional Pain Medicine Colonia, NJ Medical Doctor

NPI 1639574429 CMS profile 5700666

1503 Saint Georges Ave, Colonia, NJ 07067

Open in the dashboard

General payments

$15,352

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Shah of Colonia, NJ is reported in the CMS Open Payments database as having received $15,352 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,005 11
2024 General $865 9
2023 General $1,088 8
2022 General $4,852 20
2021 General $3,639 23
2020 General $316 6
2019 General $3,588 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Shah
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jay Shah were reported at $1,005. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jay Shah Interventional Pain Medicine median Middle half National median
2019 $3,588 $684 $216–$2,079 $163
2020 $316 $382 $122–$1,109 $114
2021 $3,639 $552 $167–$1,554 $132
2022 $4,852 $605 $187–$1,924 $149
2023 $1,088 $671 $195–$1,915 $160
2024 $865 $684 $206–$1,837 $164
2025 $1,005 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Painteq LLC $5,784 24 payments
  2. Medtronic USA, Inc. $2,978 8 payments
  3. Vertos Medical, Inc. $2,655 10 payments
  4. Abbott Laboratories $1,750 19 payments
  5. Boston Scientific Corporation $1,174 16 payments
  6. Medtronic, Inc. $362 4 payments
  7. Stryker Corporation $173 1 payment
  8. Royal Biologics $134 1 payment
  9. Vertiflex, Inc. $89 1 payment
  10. Horizon Therapeutics plc $65 5 payments
  11. Other $188 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,471 90 payments
  2. Travel and Lodging $2,481 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
  4. Compensation for serving as faculty or as a speaker for a medical education program $800 2 payments
  5. Consulting Fee $200 1 payment
Products named General payments · program years 2019–2025
  1. PAINTEQ $5,784 24 payments
  2. INTELLIS $2,955 7 payments
  3. mild Device Kit $2,603 9 payments
  4. IonicRF Generator $800 2 payments
  5. Proclaim Family of SCS IPGs $660 14 payments
  6. UNID_PASS $317 2 payments
  7. Emerge Push $221 2 payments
  8. AVVIGO Guidance System $203 2 payments
  9. Proclaim DRG IPG $200 1 payment
  10. Superion $183 4 payments
  11. Other $1,083 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$102

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tizanidine Hcl Generic 14 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$3,355

Medicare's payments for the services billed

Medicare patients

13

Average age 70

Services billed

159

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record